武田制药Takeda Pharmaceutical（TAK）2024年ESG数据手册「NYSE」（英文版）（79页）.pdf

1、Takeda 2024 ESG DatabookFiscal Year Ended March 31,2024CORPORATE PHILOSOPHY METRICSEXPLANATION OF CORPORATE PHILOSOPHY METRICSPatient ImperativePeople ImperativePlanet ImperativeBusinessESG METRICSPatient Access to MedicinesPeople Talent Management Health&Safety DE&I Women in the WorkforcePlanet Min

2、imizing Environmental Impact Decarbonizing Conserving Natural Resources Environmental Management SystemsValues-Based GovernanceEXPLANATION OF ESG METRICSASSURANCE REPORT331548782TAKEDA 2024 ESG DATABOOKCorporate PhilosophyMetrics3For Takedas value creation model and how it relates to Corporate Philo

3、sophy Metrics,see 2024 Annual Integrated Report(page 11).3EXPLANATION OF CORPORATE PHILOSOPHY METRICS ESG METRICS ASSURANCE REPORTCORPORATE PHILOSOPHY METRICS TAKEDA 2024 ESG DATABOOKEXPLANATION OF ESG METRICSWHY IT MATTERSMETRICSFY2022FY2023PATIENTWe put patients at the center of everything we do.O

4、ur long-term success is based on discovering,developing and delivering life-transforming,safe and affordable medicines and vaccines that enhance the well-being of patients,communities and countries.We create a competitive advantage with our ability to bring innovative products to market in a timely

5、fashion.Building and maintaining the trust of stakeholders including health care professionals,customers,regulators and patients is also crucial for our sustainable business.To achieve this,we prioritize making our products affordable and accessible through reimbursement and patient assistance progr

6、ams(PAPs).Additionally,ensuring transparency through disclosures of clinical trial results and quality inspection results and securing uninterrupted supply plays a vital role.Achieving Pipeline Milestones#of pivotal study starts and approvals1829Disclosing Clinical Trial Results%of achievement for t